These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31614005)

  • 1. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer.
    Shao L; Kahraman N; Yan G; Wang J; Ozpolat B; Ittmann M
    Prostate; 2020 Jan; 80(1):65-73. PubMed ID: 31614005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors.
    Shao L; Tekedereli I; Wang J; Yuca E; Tsang S; Sood A; Lopez-Berestein G; Ozpolat B; Ittmann M
    Clin Cancer Res; 2012 Dec; 18(24):6648-57. PubMed ID: 23052253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
    Marín-Aguilera M; Reig Ò; Milà-Guasch M; Font A; Domènech M; Rodríguez-Vida A; Carles J; Suárez C; Del Alba AG; Jiménez N; Victoria I; Sala-González N; Ribal MJ; López S; Etxaniz O; Anguera G; Maroto P; Fernández PL; Prat A; Mellado B
    Int J Cancer; 2019 Oct; 145(7):1970-1981. PubMed ID: 30807643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer.
    Urbinati G; Ali HM; Rousseau Q; Chapuis H; Desmaële D; Couvreur P; Massaad-Massade L
    PLoS One; 2015; 10(5):e0125277. PubMed ID: 25933120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
    Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H
    Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
    Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
    Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer.
    Xu Z; Wang Y; Xiao ZG; Zou C; Zhang X; Wang Z; Wu D; Yu S; Chan FL
    Oncogene; 2018 Nov; 37(48):6259-6274. PubMed ID: 30042415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers.
    Xu WW; Liu DY; Cao YC; Wang XY
    Int J Nanomedicine; 2017; 12():6461-6470. PubMed ID: 28919747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
    Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
    Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
    [No Abstract]   [Full Text] [Related]  

  • 10. KLK3, PCA3, and TMPRSS2-ERG expression in the peripheral blood mononuclear cell fraction from castration-resistant prostate cancer patients and response to docetaxel treatment.
    Dijkstra S; Leyten GH; Jannink SA; de Jong H; Mulders PF; van Oort IM; Schalken JA
    Prostate; 2014 Sep; 74(12):1222-30. PubMed ID: 25043536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression.
    Yin L; Rao P; Elson P; Wang J; Ittmann M; Heston WD
    PLoS One; 2011; 6(6):e21319. PubMed ID: 21731703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Celastrol suppresses tumor cell growth through targeting an AR-ERG-NF-κB pathway in TMPRSS2/ERG fusion gene expressing prostate cancer.
    Shao L; Zhou Z; Cai Y; Castro P; Dakhov O; Shi P; Bai Y; Ji H; Shen W; Wang J
    PLoS One; 2013; 8(3):e58391. PubMed ID: 23554889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth.
    Mohamed AA; Xavier CP; Sukumar G; Tan SH; Ravindranath L; Seraj N; Kumar V; Sreenath T; McLeod DG; Petrovics G; Rosner IL; Srivastava M; Strovel J; Malhotra SV; LaRonde NA; Dobi A; Dalgard CL; Srivastava S
    Cancer Res; 2018 Jul; 78(13):3659-3671. PubMed ID: 29712692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NPRL2 promotes docetaxel chemoresistance in castration resistant prostate cancer cells by regulating autophagy through the mTOR pathway.
    Luo S; Shao L; Chen Z; Hu D; Jiang L; Tang W
    Exp Cell Res; 2020 May; 390(2):111981. PubMed ID: 32234375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
    Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
    Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of FAK inhibitor VS-6063 (defactinib) on docetaxel efficacy in prostate cancer.
    Lin HM; Lee BY; Castillo L; Spielman C; Grogan J; Yeung NK; Kench JG; Stricker PD; Haynes AM; Centenera MM; Butler LM; Shreeve SM; Horvath LG; Daly RJ
    Prostate; 2018 Mar; 78(4):308-317. PubMed ID: 29314097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
    Liu B; Gu X; Huang T; Luan Y; Ding X
    Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
    Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer.
    Knuuttila M; Mehmood A; Mäki-Jouppila J; Ryberg H; Taimen P; Knaapila J; Ettala O; Boström PJ; Ohlsson C; Venäläinen MS; Laiho A; Elo LL; Sipilä P; Mäkelä SI; Poutanen M
    Endocr Relat Cancer; 2018 Sep; 25(9):807-819. PubMed ID: 29773553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
    BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.